{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:43:23Z","timestamp":1786985003219,"version":"build-2736575974"},"reference-count":238,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bbcan.2025.189515","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T07:43:41Z","timestamp":1765871021000},"page":"189515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Advancements in breast cancer mRNA vaccines: Current development and future prospects"],"prefix":"10.1016","volume":"1881","author":[{"given":"Wen","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyorgy","family":"Hutvagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Rangel-Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0005","first-page":"12","article-title":"Cancer statistics","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bbcan.2025.189515_bb0010","series-title":"Breast Cancer","author":"Orgnization","year":"2024"},{"issue":"10286","key":"10.1016\/j.bbcan.2025.189515_bb0015","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bbcan.2025.189515_bb0020","first-page":"721","article-title":"Breast cancer: an overview of current therapeutic strategies, challenge, and perspectives","volume":"15","author":"Wang","year":"2023","journal-title":"Brest cancer (Dove Medical Press)"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb0025","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1093\/annonc\/mdh302","article-title":"Primary chemotherapy for breast cancer: the evidence and the future","volume":"15","author":"Mano","year":"2004","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189515_bb0030","first-page":"663","article-title":"Adjuvant endocrine therapy in premenopausal women with breast cancer","volume":"13","author":"Kadakia","year":"2015","journal-title":"Clin. Adv. Hematol. Oncol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2020.102908","article-title":"A literature review of treatment-specific clinical prediction models in patients with breast cancer","volume":"148","author":"Modi","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb0040","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/jpm11080808","article-title":"Durocher breast cancer treatments: updates and new challenges","volume":"11","author":"Burguin","year":"2021","journal-title":"J. Person. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb0045","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.600573","article-title":"Immune checkpoint inhibitors in triple negative breast cancer treatment: promising future prospects","volume":"10","author":"Thomas","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0050","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/cancers16010124","article-title":"Engineered adoptive T-cell therapies for breast cancer: current progress, challenges, and potential","volume":"16","author":"Chamorro","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.bbcan.2025.189515_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2024.102831","article-title":"The landscape of combining immune checkpoint inhibitors with novel therapies: secret alliances against breast cancer","volume":"130","author":"Rebaudi","year":"2024","journal-title":"Cancer Treat. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0060","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.bbcan.2025.189515_bb0065","article-title":"Breast cancer vaccines: disappointing or promising?","volume":"13","author":"Zhu","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0070","article-title":"CD8(+) T cells in SARS-CoV-2 induced disease and cancer-clinical perspectives","volume":"13","author":"Mortezaee","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0075","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/ehm.10.80","article-title":"Vaccines as consolidation therapy for myeloid leukemia","volume":"4","author":"Alatrash","year":"2011","journal-title":"Expert Rev. Hematol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0080","first-page":"5","article-title":"Bioactive peptides for anticancer therapies","volume":"4","author":"Zhang","year":"2023","journal-title":"Biomater. Transl."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s11658-022-00332-w","article-title":"Anti-cancer peptide-based therapeutic strategies in solid tumors","volume":"27","author":"Karami Fath","year":"2022","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0090","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.3390\/molecules28031148","article-title":"Anti-cancer peptides: status and future prospects","volume":"28","author":"Ghaly","year":"2023","journal-title":"Molecules (Basel, Switzerland)"},{"key":"10.1016\/j.bbcan.2025.189515_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2023.154735","article-title":"Breast cancer vaccines; A comprehensive and updated review","volume":"249","author":"Al-Hawary","year":"2023","journal-title":"Pathol. Res. Pract."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12929-024-01102-w","article-title":"Advances in nucleic acid-based cancer vaccines","volume":"32","author":"Liao","year":"2025","journal-title":"J. Biomed. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0105","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4949","key":"10.1016\/j.bbcan.2025.189515_bb0110","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0115","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.bbcan.2025.189515_bb0120","article-title":"Recent advances in mRNA cancer vaccines: meeting challenges and embracing opportunities","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"issue":"10427","key":"10.1016\/j.bbcan.2025.189515_bb0125","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0130","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.bbcan.2025.189515_bb0135","article-title":"155P BNT113 + pembrolizumab as first-line treatment in patients with unresectable recurrent\/metastatic HNSCC: preliminary safety data from AHEAD-MERIT","volume":"16","author":"Klinghammer","year":"2022","journal-title":"Immuno-Oncol. Technol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0140","article-title":"Technological breakthroughs and advancements in the application of mRNA vaccines: a comprehensive exploration and future prospects","volume":"16","author":"Wei","year":"2025","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0145","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s12672-025-02542-y","article-title":"Advances in mRNA vaccine therapy for breast cancer research","volume":"16","author":"Li","year":"2025","journal-title":"Discov. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0150","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12985-025-02645-6","article-title":"Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications","volume":"22","author":"Leong","year":"2025","journal-title":"Virol. J."},{"key":"10.1016\/j.bbcan.2025.189515_bb0155","first-page":"12","article-title":"Recent progress on therapeutic vaccines for breast cancer","author":"Zhang","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0160","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ijms22020779","article-title":"Cancer vaccines, treatment of the future: with emphasis on HER2-positive breast cancer","volume":"22","author":"Pallerla","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189515_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2025.102303","article-title":"Postoperative complications and their risk factors in breast cancer patients treated with neoadjuvant chemotherapy","volume":"63","author":"K\u00e4hk\u00f6nen","year":"2025","journal-title":"Surg. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0170","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5455\/aim.2013.21.16-19","article-title":"Criteria and procedures for breast conserving surgery","volume":"21","author":"Fajdic","year":"2013","journal-title":"Acta Inform. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb0175","unstructured":"Kontos, M. and Springer International Publishing: Cham. p. 411-423."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0180","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ijrobp.2013.11.232","article-title":"The impact of radiation therapy on the risk of lymphedema after treatment for breast cancer: a prospective cohort study","volume":"88","author":"Warren","year":"2014","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.bbcan.2025.189515_bb0185","article-title":"An update on breast cancer chemotherapy-associated toxicity and their management approaches","volume":"9","author":"Langeh","year":"2023","journal-title":"Health Sci. Rev."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0190","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2174\/092986711794480177","article-title":"Endocrine therapy of breast cancer","volume":"18","author":"Lumachi","year":"2011","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.bbcan.2025.189515_bb0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2021.111322","article-title":"Mechanisms of endocrine therapy resistance in breast cancer","volume":"532","author":"Rasha","year":"2021","journal-title":"Mol. Cell. Endocrinol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0200","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.maturitas.2013.09.008","article-title":"Targeted cancer therapy--are the days of systemic chemotherapy numbered?","volume":"76","author":"Joo","year":"2013","journal-title":"Maturitas"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0205","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41392-024-02108-4","article-title":"Breast cancer: pathogenesis and treatments","volume":"10","author":"Xiong","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189515_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115209","article-title":"Targeted therapy for breast cancer: an overview of drug classes and outcomes","volume":"204","author":"Jacobs","year":"2022","journal-title":"Biochem. Pharmacol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0215","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S1470-2045(19)30804-6","article-title":"CDK4\/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis","volume":"21","author":"Gao","year":"2020","journal-title":"Lancet Oncol."},{"issue":"53","key":"10.1016\/j.bbcan.2025.189515_bb0220","doi-asserted-by":"crossref","DOI":"10.1093\/jncimonographs\/lgz008","article-title":"Potential successes and challenges of targeted cancer therapies","volume":"2019","author":"Keefe","year":"2019","journal-title":"JNCI Monogr."},{"key":"10.1016\/j.bbcan.2025.189515_bb0225","article-title":"Clinical progress of PD-1\/L1 inhibitors in breast cancer immunotherapy","volume":"11","author":"Chen","year":"2022","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0230","first-page":"86","article-title":"A review of cancer immunotherapy toxicity","volume":"70","author":"Kennedy","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0235","doi-asserted-by":"crossref","first-page":"526","DOI":"10.3390\/jpm13030526","article-title":"Immunotherapy targeting PD-1\/PD-L1 in early-stage triple-negative breast cancer","volume":"13","author":"Yang","year":"2023","journal-title":"J. Person. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0240","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s40364-024-00644-3","article-title":"mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends","volume":"12","author":"Gao","year":"2024","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0245","doi-asserted-by":"crossref","DOI":"10.1083\/jcb.202110137","article-title":"Endosomal escape of delivered mRNA from endosomal recycling tubules visualized at the nanoscale","volume":"221","author":"Paramasivam","year":"2022","journal-title":"J. Cell Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0250","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.3390\/jpm14111092","article-title":"Naguib advances in mRNA LNP-based cancer vaccines: mechanisms, formulation aspects, challenges, and future directions","volume":"14","author":"Ramadan","year":"2024","journal-title":"J. Person. Med."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0255","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/s41573-021-00283-5","article-title":"mRNA vaccines for infectious diseases: principles, delivery and clinical translation","volume":"20","author":"Chaudhary","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0260","doi-asserted-by":"crossref","first-page":"2969","DOI":"10.1016\/j.apsb.2022.03.011","article-title":"mRNA cancer vaccines: advances, trends and challenges","volume":"12","author":"He","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.bbcan.2025.189515_bb0265","series-title":"In Vitro Transcribed RNA-Based Platform Vaccines: Past, Present, and Future","first-page":"1600","volume":"11","author":"Perenkov","year":"2023"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0270","doi-asserted-by":"crossref","DOI":"10.1002\/EXP.20210146","article-title":"From structural design to delivery: mRNA therapeutics for cancer immunotherapy","volume":"4","author":"Zhou","year":"2024","journal-title":"Exploration"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189515_bb0275","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1089\/hum.2017.121","article-title":"Improvement of in vivo expression of genes delivered by self-amplifying RNA using vaccinia virus immune evasion proteins","volume":"28","author":"Beissert","year":"2017","journal-title":"Hum. Gene Ther."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0280","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1016\/j.ymthe.2025.03.060","article-title":"The advent of clinical self-amplifying RNA vaccines","volume":"33","author":"Casmil","year":"2025","journal-title":"Mol. Ther."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0285","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/v17040566","article-title":"Self-amplifying RNA: advantages and challenges of a versatile platform for vaccine development","volume":"17","author":"Vallet","year":"2025","journal-title":"Viruses"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0290","doi-asserted-by":"crossref","first-page":"R580","DOI":"10.1186\/bcr1199","article-title":"Prime\u2013boost vaccination with plasmid and adenovirus gene vaccines control HER2\/neu+metastatic breast cancer in mice","volume":"7","author":"Wang","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189515_bb0295","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1158\/1078-0432.CCR-18-3102","article-title":"Vaccine-induced memory CD8+ T cells provide clinical benefit in HER2 expressing breast cancer: a mouse to human translational study","volume":"25","author":"Crosby","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2025.189515_bb0300","first-page":"A255","article-title":"223\u00a0A UNITE<sup>\u00ae<\/sup>-based self-amplifying RNA vaccine advances anti-tumor immunity in a murine triple-negative breast cancer model","volume":"12","author":"Shen","year":"2024","journal-title":"J. ImmunoTher. Cancer"},{"issue":"14","key":"10.1016\/j.bbcan.2025.189515_bb0305","doi-asserted-by":"crossref","first-page":"5130","DOI":"10.3390\/ijms21145130","article-title":"Self-amplifying RNA viruses as RNA vaccines","volume":"21","author":"Lundstrom","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0310","doi-asserted-by":"crossref","first-page":"9435","DOI":"10.1007\/s00432-023-04805-z","article-title":"mRNA vaccination in breast cancer: current progress and future direction","volume":"149","author":"Jiang","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0315","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.4161\/hv.29475","article-title":"Overexpressed oncogenic tumor-self antigens","volume":"10","author":"Bright","year":"2014","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0320","article-title":"The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy","volume":"2012","author":"Mitri","year":"2012","journal-title":"Chemother. Res. Pract."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0325","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1186\/bcr1515","article-title":"MUC1 alters oncogenic events and transcription in human breast cancer cells","volume":"8","author":"Hattrup","year":"2006","journal-title":"Breast Cancer Res."},{"issue":"35","key":"10.1016\/j.bbcan.2025.189515_bb0330","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000011794","article-title":"The prognostic significance of hTERT overexpression in cancers: a systematic review and meta-analysis","volume":"97","author":"Wang","year":"2018","journal-title":"Medicine"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0335","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1038\/bjc.1994.225","article-title":"p53 mutations and overexpression in locally advanced breast cancers","volume":"69","author":"Faille","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bbcan.2025.189515_bb0340","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ceb.2015.08.002","article-title":"The MAGE protein family and cancer","volume":"37","author":"Weon","year":"2015","journal-title":"Curr. Opin. Cell Biol."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0345","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0038783","article-title":"NY-ESO-1 cancer testis antigen demonstrates high immunogenicity in triple negative breast cancer","volume":"7","author":"Ademuyiwa","year":"2012","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0350","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s12967-023-04030-9","article-title":"Targeting KK-LC-1 inhibits malignant biological behaviors of triple-negative breast cancer","volume":"21","author":"Zhu","year":"2023","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0355","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.3390\/diagnostics13061202","article-title":"Mammaglobin-A expression is highly specific for tumors derived from the breast, the female genital tract, and the salivary gland","volume":"13","author":"Gorbokon","year":"2023","journal-title":"Diagnostics"},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0360","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/sj.bjc.6602738","article-title":"Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic disease","volume":"93","author":"Zidan","year":"2005","journal-title":"Br. J. Cancer"},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0365","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/vaccines12070808","article-title":"HER2-CD3-Fc bispecific antibody-encoding mrna delivered by lipid nanoparticles suppresses HER2-positive tumor growth","volume":"12","author":"Hu","year":"2024","journal-title":"Vaccines"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0370","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb0375","article-title":"Neoantigen: a new breakthrough in tumor immunotherapy","volume":"12","author":"Zhang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0380","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.3389\/fimmu.2019.01856","article-title":"Mutation-derived neoantigens for cancer immunotherapy","volume":"10","author":"Castle","year":"2019","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0385","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1038\/s41467-018-06146-9","article-title":"Somatic Trp53 mutations differentially drive breast cancer and evolution of metastases","volume":"9","author":"Zhang","year":"2018","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0390","first-page":"689","article-title":"PIK3CA H1047R mutation associated with a lower pathological complete response rate in triple-negative breast cancer patients treated with anthracycline-taxane-based neoadjuvant","volume":"52","author":"Guo","year":"2020","journal-title":"Chemotherapy"},{"issue":"9","key":"10.1016\/j.bbcan.2025.189515_bb0395","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2013.38","article-title":"Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R","volume":"2","author":"Meyer","year":"2013","journal-title":"Oncogenesis"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0400","doi-asserted-by":"crossref","first-page":"4577","DOI":"10.1038\/ncomms5577","article-title":"Recurrent ESR1\u2013CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers","volume":"5","author":"Veeraraghavan","year":"2014","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0405","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0410","doi-asserted-by":"crossref","first-page":"394","DOI":"10.18632\/oncotarget.27877","article-title":"Tumor mutational burden as a predictor of immunotherapy response in breast cancer","volume":"12","author":"O\u2019Meara","year":"2021","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0415","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cac2.12511","article-title":"Rescue of p53 functions by in vitro-transcribed mRNA impedes the growth of high-grade serous ovarian cancer","volume":"44","author":"Raab","year":"2024","journal-title":"Cancer Communications"},{"key":"10.1016\/j.bbcan.2025.189515_bb0420","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120586","article-title":"mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability","volume":"601","author":"Schoenmaker","year":"2021","journal-title":"Int. J. Pharm."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0425","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.3390\/pharmaceutics15071972","article-title":"Recent advancement in mRNA vaccine development and applications","volume":"15","author":"Al Fayez","year":"2023","journal-title":"Pharmaceutics"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189515_bb0430","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.bbcan.2025.189515_bb0435","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jconrel.2024.08.030","article-title":"Enhancing RNA-lipid nanoparticle delivery: Organ- and cell-specificity and barcoding strategies","volume":"375","author":"Wei","year":"2024","journal-title":"J. Control. Release"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0440","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3390\/pharmaceutics12020102","article-title":"Opportunities and challenges in the delivery of mRNA-based vaccines","volume":"12","author":"Wadhwa","year":"2020","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0445","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral vector platforms within the gene therapy landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189515_bb0450","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117550","article-title":"Bacterial and viral vectors as vaccine delivery vehicles for breast cancer therapy","volume":"250","author":"Shanmugaraj","year":"2020","journal-title":"Life Sci."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189515_bb0455","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.3390\/biomedicines10092142","article-title":"Recombinant viral vectors for therapeutic programming of tumour microenvironment: advantages and limitations","volume":"10","author":"Spunde","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0460","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1177\/1535676019899502","article-title":"Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges","volume":"25","author":"Ghosh","year":"2025","journal-title":"Appl. Biosaf."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0465","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.3390\/cancers12051139","article-title":"Expanding the spectrum of adenoviral vectors for cancer therapy","volume":"12","author":"Gao","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0470","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/mt.2009.319","article-title":"Recent advances in lentiviral vector development and applications","volume":"18","author":"M\u00e1trai","year":"2010","journal-title":"Mol. Ther."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0475","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a035873","article-title":"A history of cancer research: retroviral insertional mutagenesis","volume":"15","author":"Lipsick","year":"2023","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0480","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jconrel.2016.01.001","article-title":"Adeno-associated virus (AAV) vectors in cancer gene therapy","volume":"240","author":"Santiago-Ortiz","year":"2016","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0485","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","article-title":"Adeno-associated virus as a delivery vector for gene therapy of human diseases","volume":"9","author":"Wang","year":"2024","journal-title":"Sig. Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0490","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1146\/annurev-virology-101416-041936","article-title":"Overcoming the host immune response to adeno-associated virus gene delivery vectors: the race between clearance, tolerance, neutralization, and escape","volume":"4","author":"Mingozzi","year":"2017","journal-title":"Annu. Rev. Virol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0495","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/21645515.2020.1757989","article-title":"Viral gene delivery vectors: the next generation medicines for immune-related diseases","volume":"17","author":"De Haan","year":"2017","journal-title":"Hum. Vaccin. Immunother."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0500","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","article-title":"Non-viral vectors in gene therapy: recent development, challenges, and prospects","volume":"23","author":"Zu","year":"2021","journal-title":"AAPS J."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb0505","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3390\/genes13081370","article-title":"Appraisal for the potential of viral and nonviral vectors in gene therapy: a review","volume":"13","author":"Butt","year":"2022","journal-title":"Genes"},{"key":"10.1016\/j.bbcan.2025.189515_bb0510","first-page":"71","article-title":"Formulation and delivery technologies for mRNA vaccines","volume":"440","author":"Zeng","year":"2022","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0515","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-1-4939-3625-0_15","article-title":"Delivery of synthetic mRNA encoding FOXP3 antigen into dendritic cells for inflammatory breast cancer immunotherapy","volume":"1428","author":"Devi","year":"2016","journal-title":"Methods Mol. Biol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0520","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.3390\/ijms20112776","article-title":"A critical review of electroporation as a plasmid delivery system in mouse skeletal muscle","volume":"20","author":"Soko\u0142owska","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.bbcan.2025.189515_bb0525","first-page":"420","article-title":"The effects of interphase and interpulse delays and pulse widths on induced muscle contractions, pain and therapeutic efficacy in electroporation-based therapies","volume":"10","author":"Cvetkoska","year":"2023","journal-title":"J. Cardiovasc. Dev. Dis."},{"issue":"21","key":"10.1016\/j.bbcan.2025.189515_bb0530","doi-asserted-by":"crossref","DOI":"10.3390\/app122110821","article-title":"Electroporation in clinical applications\u2014the potential of gene electrotransfer and electrochemotherapy","volume":"12","author":"Rakoczy","year":"2022","journal-title":"Appl. Sci."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0535","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s12929-024-01080-z","article-title":"Current landscape of mRNA technologies and delivery systems for new modality therapeutics","volume":"31","author":"Lu","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0540","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.apsb.2023.10.012","article-title":"Lipid nanovehicles overcome barriers to systemic RNA delivery: lipid components, fabrication methods, and rational design","volume":"14","author":"Yan","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0545","doi-asserted-by":"crossref","first-page":"563","DOI":"10.3390\/pharmaceutics16040563","article-title":"Modulating the nature of ionizable lipids and number of layers in hyaluronan-decorated lipid nanoparticles for in vitro delivery of RNAi","volume":"16","author":"Passos Gibson","year":"2024","journal-title":"Pharmaceutics"},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb0550","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.3390\/ijms24032700","article-title":"A comprehensive review of mRNA vaccines","volume":"24","author":"Gote","year":"2023","journal-title":"Int. J. Mol. Sci."},{"issue":"42","key":"10.1016\/j.bbcan.2025.189515_bb0555","doi-asserted-by":"crossref","first-page":"29045","DOI":"10.1021\/acsnano.4c10154","article-title":"Tetrahydropyrimidine ionizable lipids for efficient mRNA delivery","volume":"18","author":"Isaac","year":"2024","journal-title":"ACS Nano"},{"issue":"22","key":"10.1016\/j.bbcan.2025.189515_bb0560","doi-asserted-by":"crossref","first-page":"7534","DOI":"10.1039\/D1BM00866H","article-title":"Boosting ionizable lipid nanoparticle-mediated in vivo mRNA delivery through optimization of lipid amine-head groups","volume":"9","author":"Ding","year":"2021","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.bbcan.2025.189515_bb0565","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1039\/D3TB00516J","article-title":"A fluorinated ionizable lipid improves the mRNA delivery efficiency of lipid nanoparticles","volume":"11","author":"Huo","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"45","key":"10.1016\/j.bbcan.2025.189515_bb0570","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202404684","article-title":"Discovery of ketal-ester ionizable lipid nanoparticle with reduced hepatotoxicity, enhanced spleen tropism for mRNA vaccine delivery","volume":"11","author":"Lv","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2025.189515_bb0575","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.addr.2016.01.022","article-title":"The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery","volume":"99","author":"Cheng","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189515_bb0580","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202303857","article-title":"Modulating lipid nanoparticles with histidinamide-conjugated cholesterol for improved intracellular delivery of mRNA","volume":"13","author":"Jung","year":"2024","journal-title":"Adv. Healthc. Mater."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb0585","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1021\/acsabm.3c00721","article-title":"Advances in nonviral mRNA delivery materials and their application as vaccines for melanoma therapy","volume":"7","author":"Neill","year":"2024","journal-title":"ACS Appl. Bio Mater."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0590","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13045-024-01535-8","article-title":"Nanoparticles in tumor microenvironment remodeling and cancer immunotherapy","volume":"17","author":"Lu","year":"2024","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0595","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1038\/s41467-025-63415-0","article-title":"Modulating tumor collagen fiber alignment for enhanced lung cancer immunotherapy via inhaled RNA","volume":"16","author":"Hu","year":"2025","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.bbcan.2025.189515_bb0600","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.3390\/ma14226812","article-title":"Polymer-based nanosystems-a versatile delivery approach","volume":"14","author":"Niculescu","year":"2021","journal-title":"Materials"},{"key":"10.1016\/j.bbcan.2025.189515_bb0605","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117372","article-title":"Biophysical translational paradigm of polymeric nanoparticle: Embarked advancement to brain tumor therapy","volume":"179","author":"Naser","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0610","doi-asserted-by":"crossref","first-page":"738","DOI":"10.7150\/thno.84291","article-title":"Nanoparticle technology for mRNA: delivery strategy, clinical application and developmental landscape","volume":"14","author":"Li","year":"2024","journal-title":"Theranostics"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0615","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.matt.2022.03.006","article-title":"The roles of polymers in mRNA delivery","volume":"5","author":"Huang","year":"2022","journal-title":"Matter"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0620","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.ymthe.2005.02.010","article-title":"A two-stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer\/therapy","volume":"11","author":"Moghimi","year":"2005","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0625","first-page":"120","article-title":"mRNA vaccine nanoplatforms and innate","volume":"16","author":"Wei","year":"2024","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0630","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201801359","article-title":"Poly(\u03b2-amino esters): synthesis, formulations, and their biomedical applications","volume":"8","author":"Liu","year":"2019","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bbcan.2025.189515_bb0635","series-title":"PLGA-Based Nanomedicine: History of Advancement and Development in Clinical Applications of Multiple Diseases","first-page":"2728","volume":"14","author":"Alsaab","year":"2022"},{"issue":"10","key":"10.1016\/j.bbcan.2025.189515_bb0640","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202400180","article-title":"PLGA nanoparticles coated with activated dendritic cell membrane can prolong protein expression and improve the efficacy of mRNA","volume":"7","author":"Xu","year":"2024","journal-title":"Adv. Therap."},{"issue":"15","key":"10.1016\/j.bbcan.2025.189515_bb0645","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.202202688","article-title":"Polymer-based mRNA delivery strategies for advanced therapies","volume":"12","author":"Yang","year":"2023","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.bbcan.2025.189515_bb0650","first-page":"1659","article-title":"In-vitro transcribed mRNA delivery using PLGA\/PEI nanoparticles into human monocyte-derived dendritic cells","volume":"18","author":"Sharifnia","year":"2019","journal-title":"Iran. J. Pharm. Res."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189515_bb0675","doi-asserted-by":"crossref","first-page":"6209","DOI":"10.3390\/cancers13246209","article-title":"The role of breast cancer stem cells in chemoresistance and metastasis in triple-negative breast cancer","volume":"13","author":"He","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0655","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0660","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2021.101298","article-title":"Combination of CTLA-4 blockade with MUC1 mRNA nanovaccine induces enhanced anti-tumor CTL activity by modulating tumor microenvironment of triple negative breast cancer","volume":"15","author":"Lin","year":"2022","journal-title":"Transl. Oncol."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0670","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/pharmaceutics16070940","article-title":"\u03b1-lactalbumin mRNA-LNP evokes an anti-tumor effect combined with surgery in triple-negative breast cancer","volume":"16","author":"He","year":"2024","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0665","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s10549-010-0844-9","article-title":"High immunogenic potential of p53 mRNA-transfected dendritic cells in patients with primary breast cancer","volume":"125","author":"Met","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.bbcan.2025.189515_bb0680","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.omto.2021.05.006","article-title":"CD133 mRNA-transfected dendritic cells induce coordinated cytotoxic and helper T cell responses against breast cancer stem cells","volume":"22","author":"Tay","year":"2021","journal-title":"Mol. Ther. Oncolyt."},{"issue":"8_Supplement_1","key":"10.1016\/j.bbcan.2025.189515_bb0685","doi-asserted-by":"crossref","first-page":"3525","DOI":"10.1158\/1538-7445.AM2025-3525","article-title":"Abstract 3525: Neo20 mRNA vaccine induces neoantigen-specific T cell immunity in humanized patient-derived xenograft mouse models of triple-negative breast cancer","volume":"85","author":"Chervo","year":"2025","journal-title":"Cancer Res."},{"issue":"26","key":"10.1016\/j.bbcan.2025.189515_bb0690","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301606120","article-title":"Biodegradable lipophilic polymeric mRNA nanoparticles for ligand-free targeting of splenic dendritic cells for cancer vaccination","volume":"120","author":"Ben-Akiva","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189515_bb0695","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202410998","article-title":"A polymeric mRNA vaccine featuring enhanced site-specific mRNA delivery and inherent STING-stimulating performance for tumor immunotherapy","volume":"37","author":"Guo","year":"2025","journal-title":"Adv. Mater."},{"key":"10.1016\/j.bbcan.2025.189515_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104143","article-title":"Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity","volume":"354","author":"Mai","year":"2020","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0705","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.actbio.2023.07.059","article-title":"Immunotherapeutic treatment of lung cancer and bone metastasis with a mPLA\/mRNA tumor vaccine","volume":"169","author":"Ma","year":"2023","journal-title":"Acta Biomater."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0710","doi-asserted-by":"crossref","first-page":"8392","DOI":"10.1021\/acsnano.3c13039","article-title":"Antiangiogenic therapeutic mRNA delivery using lung-selective polymeric nanomedicine for lung cancer treatment","volume":"18","author":"Le","year":"2024","journal-title":"ACS Nano"},{"issue":"24","key":"10.1016\/j.bbcan.2025.189515_bb0715","article-title":"All-trans-retinoic acid-adjuvanted mRNA vaccine induces mucosal anti-tumor immune responses for treating colorectal cancer","volume":"11","author":"Li","year":"2024","journal-title":"Adv. Sci."},{"key":"10.1016\/j.bbcan.2025.189515_bb0720","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120431","article-title":"Adjuvant-pulsed mRNA vaccine nanoparticle for immunoprophylactic and therapeutic tumor suppression in mice","volume":"266","author":"Islam","year":"2021","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0725","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2024.2373526","article-title":"Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity","volume":"13","author":"Xu","year":"2024","journal-title":"Oncoimmunology"},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb0730","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41417-023-00587-1","article-title":"Clinical trials of self-replicating RNA-based cancer vaccines","volume":"30","author":"Morse","year":"2023","journal-title":"Cancer Gene Ther."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189515_bb0735","doi-asserted-by":"crossref","first-page":"4670","DOI":"10.1158\/1078-0432.CCR-20-0389","article-title":"Stimulation of oncogene-specific tumor-infiltrating T cells through combined vaccine and \u03b1PD-1 enable sustained antitumor responses against established HER2 breast cancer","volume":"26","author":"Crosby","year":"2020","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189515_bb0740","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2016.1207842","article-title":"mRNA-transfected dendritic cell vaccine in combination with metronomic cyclophosphamide as treatment for patients with advanced malignant melanoma","volume":"5","author":"Borch","year":"2016","journal-title":"OncoImmunology"},{"issue":"5, Supplement","key":"10.1016\/j.bbcan.2025.189515_bb0745","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jcyt.2019.03.565","article-title":"Vaccination of cancer patients with dendritic cells electroporated with mRNA encoding the wilms' tumor 1 protein (WT1): correlation of clinical effect and overall survival with T-cell response","volume":"21","author":"Berneman","year":"2019","journal-title":"Cytotherapy"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0750","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41392-023-01674-3","article-title":"Therapeutic cancer vaccines: advancements, challenges and prospects","volume":"8","author":"Fan","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189515_bb0755","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/j.annonc.2020.08.209","article-title":"88MO T-cell responses induced by an individualized neoantigen specific immune therapy in post (neo)adjuvant patients with triple negative breast cancer","volume":"31","author":"Schmidt","year":"2020","journal-title":"Ann. Oncol."},{"issue":"16_Supplement","key":"10.1016\/j.bbcan.2025.189515_bb0760","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2020-CT301","article-title":"Abstract CT301: a phase Ib study to evaluate RO7198457, an individualized Neoantigen Specific immunoTherapy (iNeST), in combination with atezolizumab in patients with locally advanced or metastatic solid tumors","volume":"80","author":"Lopez","year":"2020","journal-title":"Cancer Res."},{"issue":"Suppl. 2","key":"10.1016\/j.bbcan.2025.189515_bb0765","first-page":"A798","article-title":"767\u00a0Safety and preliminary efficacy of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L\/IL-23\/IL-36\u03b3 for intratumoral (ITu) injection, and durvalumab (IV) in TNBC, HNSCC, and melanoma","volume":"10","author":"Olson","year":"2022","journal-title":"J. ImmunoTher. Cancer"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0770","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000329","article-title":"TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma","volume":"8","author":"De Keersmaecker","year":"2020","journal-title":"J. ImmunoTher. Cancer"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0775","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2326-6066.CIR-15-0163","article-title":"Intratumoral delivery of TriMix mRNA results in T-cell activation by cross-presenting dendritic cells","volume":"4","author":"Van Lint","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.bbcan.2025.189515_bb0780","series-title":"China\u2019s Stemirna Halts mRNA Cancer Vaccine Trial, Researchers Say","author":"Doyle","year":"2024"},{"issue":"17","key":"10.1016\/j.bbcan.2025.189515_bb0785","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.3390\/cells12172159","article-title":"Cancer vaccine therapeutics: limitations and effectiveness-a literature review","volume":"12","author":"Kaczmarek","year":"2023","journal-title":"Cells"},{"issue":"16","key":"10.1016\/j.bbcan.2025.189515_bb0790","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.21037\/atm-21-1948","article-title":"A narrative review of tumor heterogeneity and challenges to tumor drug therapy","volume":"9","author":"Zhu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"9","key":"10.1016\/j.bbcan.2025.189515_bb0795","first-page":"1183","article-title":"From chaos to opportunity: decoding cancer heterogeneity for enhanced treatment strategies","volume":"12","author":"Ottaiano","year":"2023","journal-title":"Ann. Transl. Med."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0800","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12964-020-0530-4","article-title":"Tumor microenvironment complexity and therapeutic implications at a glance","volume":"18","author":"Baghban","year":"2020","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.bbcan.2025.189515_bb0805","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102429","article-title":"Therapeutic cancer vaccines: from biological mechanisms and engineering to ongoing clinical trials","volume":"109","author":"Sobhani","year":"2022","journal-title":"Cancer Treat. Rev."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0810","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1038\/nm.3394","article-title":"Microenvironmental regulation of tumor progression and metastasis","volume":"19","author":"Quail","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb0815","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.830208","article-title":"Key players of the immunosuppressive tumor microenvironment and emerging therapeutic strategies","volume":"10","author":"Park","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"issue":"24","key":"10.1016\/j.bbcan.2025.189515_bb0820","first-page":"137","article-title":"mRNA vaccines as cancer therapies","author":"Huang","year":"2024","journal-title":"Chin. Med. J."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189515_bb0825","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.3390\/ph16101384","article-title":"Tumor vaccines: unleashing the power of the immune system to fight cancer","volume":"16","author":"Liu","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0830","first-page":"3","article-title":"Implantable immune stents: a new opportunity for cancer treatment","volume":"4","author":"Chen","year":"2023","journal-title":"Biomater. Transl."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0835","doi-asserted-by":"crossref","first-page":"10635","DOI":"10.1038\/s41467-024-54877-9","article-title":"Intratumoral delivery of lipid nanoparticle-formulated mRNA encoding IL-21, IL-7, and 4-1BBL induces systemic anti-tumor immunity","volume":"15","author":"Hamouda","year":"2024","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0840","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0845","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41392-024-02002-z","article-title":"Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189515_bb0850","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1306025","article-title":"From rejection to the Nobel Prize: Karik\u00f3 and Weissman's pioneering work on mRNA vaccines, and the need for diversity and inclusion in translational immunology","volume":"14","author":"Bansal","year":"2023","journal-title":"Front. Immunol."},{"issue":"17","key":"10.1016\/j.bbcan.2025.189515_bb0855","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0860","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40364-022-00362-8","article-title":"Biological roles of RNA m5C modification and its implications in cancer immunotherapy","volume":"10","author":"Song","year":"2022","journal-title":"Biomark. Res."},{"key":"10.1016\/j.bbcan.2025.189515_bb0865","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2015.08.051","article-title":"N1-methylpseudouridine-incorporated mRNA outperforms pseudouridine-incorporated mRNA by providing enhanced protein expression and reduced immunogenicity in mammalian cell lines and mice","volume":"217","author":"Andries","year":"2015","journal-title":"J. Control. Release"},{"issue":"7993","key":"10.1016\/j.bbcan.2025.189515_bb0870","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bbcan.2025.189515_bb0875","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.jconrel.2022.12.018","article-title":"Proteoid biodynamers for safe mRNA transfection via pH-responsive nanorods enabling endosomal escape","volume":"353","author":"Lee","year":"2023","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0880","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2307800120","article-title":"Endosomal escape: a bottleneck for LNP-mediated therapeutics","volume":"121","author":"Chatterjee","year":"2024","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0885","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nbt.2614","article-title":"Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling","volume":"31","author":"Sahay","year":"2013","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.bbcan.2025.189515_bb0890","series-title":"Illuminating Endosomal Escape of Polymorphic Lipid Nanoparticles That Boost mRNA Delivery","first-page":"4289","volume":"9","author":"Herrera","year":"2021"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0895","doi-asserted-by":"crossref","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","article-title":"Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol","volume":"16","author":"Johansson","year":"2025","journal-title":"Nat. Commun."},{"issue":"7","key":"10.1016\/j.bbcan.2025.189515_bb0900","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3390\/pharmaceutics17070803","article-title":"Endo\/lysosomal-escapable lipid nanoparticle platforms for enhancing mRNA delivery in cancer therapy","volume":"17","author":"Wang","year":"2025","journal-title":"Pharmaceutics"},{"issue":"27","key":"10.1016\/j.bbcan.2025.189515_bb0905","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2301067120","article-title":"Lipid nanoparticle topology regulates endosomal escape and delivery of RNA to the cytoplasm","volume":"120","author":"Zheng","year":"2023","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0910","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1038\/s41565-024-01765-4","article-title":"Acid-degradable lipid nanoparticles enhance the delivery of mRNA","volume":"19","author":"Zhao","year":"2024","journal-title":"Nat. Nanotechnol."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0915","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202305300","article-title":"Lipid nanoparticles optimized for targeting and release of nucleic acid","volume":"36","author":"Jia","year":"2024","journal-title":"Adv. Mater."},{"issue":"14","key":"10.1016\/j.bbcan.2025.189515_bb0920","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.3390\/nano12142446","article-title":"In cellulo and in vivo comparison of cholesterol, beta-sitosterol and dioleylphosphatidylethanolamine for lipid nanoparticle formulation of mRNA","volume":"12","author":"Medjmedj","year":"2022","journal-title":"Nanomaterials"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0925","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.3390\/cells10113043","article-title":"Viral membrane fusion proteins and RNA sorting mechanisms for the molecular delivery by exosomes","volume":"10","author":"Zubarev","year":"2021","journal-title":"Cells"},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0930","doi-asserted-by":"crossref","first-page":"7174","DOI":"10.1021\/acs.langmuir.4c05176","article-title":"The interplay of endosomal escape and RNA release from polymeric nanoparticles","volume":"41","author":"Cheung","year":"2025","journal-title":"Langmuir"},{"key":"10.1016\/j.bbcan.2025.189515_bb0935","article-title":"Engineered lipid nanoparticles with synergistic dendritic cell targeting and enhanced endosomal escape for boosted mRNA cancer vaccines","volume":"34","author":"Wang","year":"2025","journal-title":"Mater. Today Bio"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0940","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2025.101436","article-title":"Why do lipid nanoparticles target the liver? Understanding of biodistribution and liver-specific tropism","volume":"33","author":"Hosseini-Kharat","year":"2025","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.bbcan.2025.189515_bb0945","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/s41565-020-0669-6","article-title":"Selective ORgan Targeting (SORT) nanoparticles for tissue specific mRNA delivery and CRISPR\/Cas gene editing","volume":"15","author":"Cheng","year":"2020","journal-title":"Nat. Nanotechnol."},{"issue":"11","key":"10.1016\/j.bbcan.2025.189515_bb0950","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1038\/s41563-025-02285-9","volume":"24","year":"2025","journal-title":"Nat. Mater."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb0955","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12916-022-02719-0","article-title":"Recommendations for robust and reproducible preclinical research in personalised medicine","volume":"21","author":"Fosse","year":"2023","journal-title":"BMC Med."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0960","doi-asserted-by":"crossref","first-page":"160","DOI":"10.5625\/lar.2018.34.4.160","article-title":"Mouse models of breast cancer in preclinical research","volume":"34","author":"Park","year":"2018","journal-title":"Lab Anim. Res."},{"key":"10.1016\/j.bbcan.2025.189515_bb0965","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984356","article-title":"(Not) Home alone: Antigen presenting cell \u2013 T Cell communication in barrier tissues","volume":"13","author":"Neuwirth","year":"2022","journal-title":"Front. Immunol."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb0970","article-title":"Patient-derived xenograft models: current status, challenges, and innovations in cancer research","volume":"12","author":"Liu","year":"2025","journal-title":"Genes & Dis."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb0975","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jncc.2022.10.001","article-title":"Patient-derived organoids (PDOs) and PDO-derived xenografts (PDOXs): New opportunities in establishing faithful pre-clinical cancer models","volume":"2","author":"Wang","year":"2022","journal-title":"J. Natl. Cancer Center"},{"key":"10.1016\/j.bbcan.2025.189515_bb0980","series-title":"mRNA-Based Vaccines and Therapeutics: An In-Depth Survey of Current and Upcoming Clinical Applications","first-page":"84","volume":"30","author":"Wang","year":"2023"},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb0985","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.3390\/life12081254","article-title":"The delivery of mRNA vaccines for therapeutics","volume":"12","author":"Nitika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.bbcan.2025.189515_bb0990","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.645210","article-title":"Vaccine inoculation route modulates early immunity and consequently antigen-specific immune response","volume":"12","author":"Rosenbaum","year":"2021","journal-title":"Front. Immunol."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb0995","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/imm.13526","article-title":"Vaccines, adjuvants and key factors for mucosal immune response","volume":"167","author":"Correa","year":"2022","journal-title":"Immunology"},{"key":"10.1016\/j.bbcan.2025.189515_bb1000","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.117858","article-title":"Revolutionizing cancer treatment: the power of dendritic cell-based vaccines in immunotherapy","volume":"184","author":"Sheykhhasan","year":"2025","journal-title":"Biomed. Pharmacother."},{"issue":"10","key":"10.1016\/j.bbcan.2025.189515_bb1005","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.3390\/cancers14102438","article-title":"Lymph nodes as anti-tumor immunotherapeutic tools: intranodal-tumor-specific antigen-pulsed dendritic cell vaccine immunotherapy","volume":"14","author":"Morisaki","year":"2022","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1010","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2217\/imt.09.43","article-title":"Directing dendritic cell immunotherapy towards successful cancer treatment","volume":"2","author":"Sabado","year":"2010","journal-title":"Immunotherapy"},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb1015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s00204-024-03912-1","article-title":"Impact of administration routes and dose frequency on the toxicology of SARS-CoV-2 mRNA vaccines in mice model","volume":"99","author":"Ahn","year":"2025","journal-title":"Arch. Toxicol."},{"issue":"16","key":"10.1016\/j.bbcan.2025.189515_bb1020","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.vaccine.2021.03.038","article-title":"mRNA vaccines manufacturing: challenges and bottlenecks","volume":"39","author":"Rosa","year":"2021","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb1025","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1080\/21645515.2020.1822136","article-title":"COVID-19 vaccine development during pandemic: gap analysis, opportunities, and impact on future emerging infectious disease development strategies","volume":"17","author":"Rele","year":"2021","journal-title":"Hum. Vaccin. Immunother."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb1030","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.xphs.2020.12.006","article-title":"Addressing the cold reality of mRNA vaccine stability","volume":"110","author":"Crommelin","year":"2021","journal-title":"J. Pharm. Sci."},{"issue":"6","key":"10.1016\/j.bbcan.2025.189515_bb1035","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.3390\/pr11061718","article-title":"Strube formulation of nucleic acids by encapsulation in lipid nanoparticles for continuous production of mrna","volume":"11","author":"Hengelbrock","year":"2023","journal-title":"Processes"},{"issue":"12","key":"10.1016\/j.bbcan.2025.189515_bb1040","doi-asserted-by":"crossref","first-page":"4327","DOI":"10.1039\/D2BM02031A","article-title":"Successful batch and continuous lyophilization of mRNA LNP formulations depend on cryoprotectants and ionizable lipids","volume":"11","author":"Lamoot","year":"2023","journal-title":"Biomater. Sci."},{"issue":"8","key":"10.1016\/j.bbcan.2025.189515_bb1045","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.1384","article-title":"mRNA vaccine in cancer therapy: current advance and future outlook","volume":"13","author":"Li","year":"2023","journal-title":"Clin. Transl. Med."},{"issue":"13","key":"10.1016\/j.bbcan.2025.189515_bb1050","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310514","article-title":"mRNA: vaccine or gene therapy? The safety regulatory issues","volume":"24","author":"Banoun","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bbcan.2025.189515_bb1055","first-page":"2","article-title":"Autoimmune and neoplastic outcomes after the mrna vaccination: the role of T regulatory cell responses","volume":"3","author":"Kyriakopoulos","year":"2024","journal-title":"Int. J. Vaccine Theory Pract. Res."},{"issue":"2","key":"10.1016\/j.bbcan.2025.189515_bb1065","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1208\/s12248-012-9339-4","article-title":"Challenges in development of nanoparticle-based therapeutics","volume":"14","author":"Desai","year":"2012","journal-title":"AAPS J."},{"issue":"5","key":"10.1016\/j.bbcan.2025.189515_bb1070","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3390\/vaccines13050473","article-title":"Considerations for mRNA product development, regulation and deployment across the lifecycle","volume":"13","author":"Skerritt","year":"2025","journal-title":"Vaccines"},{"key":"10.1016\/j.bbcan.2025.189515_bb1075","doi-asserted-by":"crossref","DOI":"10.1016\/j.biotechadv.2025.108612","article-title":"Advanced therapy medicinal products development - from guidelines to medicines in the market","volume":"83","author":"Frederico","year":"2025","journal-title":"Biotechnol. Adv."},{"key":"10.1016\/j.bbcan.2025.189515_bb1080","series-title":"Committee for Advanced Therapies (CAT). [cited 2025 05\/03].","author":"AGENCY","year":"2022"},{"key":"10.1016\/j.bbcan.2025.189515_bb1085","article-title":"20 years of legislation - how australia has responded to the challenge of regulating genetically modified organisms in the clinic","volume":"9","author":"O'Sullivan","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb1090","series-title":"Vaccine Development, Testing, and Regulation","author":"Vaccines, H.O","year":"2024"},{"key":"10.1016\/j.bbcan.2025.189515_bb1095","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.15_suppl.e18158","article-title":"Expanded access for cancer patients: The 5-year FDA CBER experience","volume":"37","author":"Colbert","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1100","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2025.2482479","article-title":"Human vaccines & immunotherapeutics: News February 2023","volume":"19","author":"Ellis","year":"2023","journal-title":"Hum. Vaccin. Immunother."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1105","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1002\/cpt.2906","article-title":"European conditional marketing authorization in a rapidly evolving treatment landscape: a comprehensive study of anticancer medicinal products in 2006\u20132020","volume":"114","author":"Bloem","year":"2023","journal-title":"Clin. Pharmacol. Therap."},{"issue":"3","key":"10.1016\/j.bbcan.2025.189515_bb1110","doi-asserted-by":"crossref","first-page":"55","DOI":"10.22270\/ijdra.v12i3.699","article-title":"Index of application status transparency and availability of public information for Project Orbis agencies","volume":"12","author":"Lee","year":"2024","journal-title":"Int. J. Drug Regul. Affairs"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1115","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s12929-024-01082-x","article-title":"Molecular targets and strategies in the development of nucleic acid cancer vaccines: from shared to personalized antigens","volume":"31","author":"Chi","year":"2024","journal-title":"J. Biomed. Sci."},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb1120","first-page":"274","article-title":"Neoantigen cancer vaccines: a new star on the horizon","volume":"21","author":"Li","year":"2023","journal-title":"Cancer Biol. Med."},{"key":"10.1016\/j.bbcan.2025.189515_bb1125","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2025.1629386","article-title":"A decade of research on genetic privacy: the findings of the GetPreCiSe Center at Vanderbilt University","volume":"16","author":"Slobogin","year":"2025","journal-title":"Front. Genet."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1130","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s13040-025-00461-w","article-title":"The ethics of data mining in healthcare: challenges, frameworks, and future directions","volume":"18","author":"Ahmed","year":"2025","journal-title":"BioData Mining"},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1135","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4103\/2229-3485.106373","article-title":"Informed consent in clinical research: revisiting few concepts and areas","volume":"4","author":"Gupta","year":"2013","journal-title":"Perspect. Clin. Res."},{"key":"10.1016\/j.bbcan.2025.189515_bb1140","series-title":"A Summary of Health Legal\u2019s Report for Australian Genomics","author":"Belcher","year":"2018"},{"issue":"4","key":"10.1016\/j.bbcan.2025.189515_bb1145","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1177\/17407745221087469","article-title":"Current recommendations\/practices for anonymising data from clinical trials in order to make it available for sharing: a scoping review","volume":"19","author":"Rodriguez","year":"2022","journal-title":"Clin. Trials"},{"key":"10.1016\/j.bbcan.2025.189515_bb1150","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13063-017-2382-9","article-title":"Data sharing in clinical trials - practical guidance on anonymising trial datasets","volume":"19","author":"Keerie","year":"2018","journal-title":"Trials"},{"key":"10.1016\/j.bbcan.2025.189515_bb1155","article-title":"Blockchain technology in supply chain management: Innovations, applications, and challenges","volume":"18","author":"Kumar","year":"2025","journal-title":"Telem. Inform. Rep."},{"key":"10.1016\/j.bbcan.2025.189515_bb1160","article-title":"Coldnet: vaccine logistics tracking by integrating the internet of things and smart contracts: an immutable and reliable approach","author":"Vilas Boas","year":"2025","journal-title":"Blockchain: Res. Appl."},{"issue":"1","key":"10.1016\/j.bbcan.2025.189515_bb1165","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/s41392-023-01579-1","article-title":"mRNA vaccines in disease prevention and treatment","volume":"8","author":"Zhang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.bbcan.2025.189515_bb1170","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114993","article-title":"mRNA: a promising platform for cancer immunotherapy","volume":"199","author":"Kong","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bbcan.2025.189515_bb1175","doi-asserted-by":"crossref","unstructured":"Raheem, K. and M. Muddassar, Design of personalized neoantigen mRNA vaccines against breast cancer patients in Pakistan based on next-generation sequencing data. Cancer Epidemiol. Biomarkers Prev., 2024. 33(9_Supplement):Abstract nr B010.","DOI":"10.1158\/1538-7755.DISP24-B010"},{"issue":"7_Supplement","key":"10.1016\/j.bbcan.2025.189515_bb1180","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-SY41-01","article-title":"Selection of targeted neoantigens for personalized cancer vaccines","volume":"84","author":"Keskin","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bbcan.2025.189515_bb1185","doi-asserted-by":"crossref","DOI":"10.1002\/adtp.202300255","article-title":"Advancing cancer immunotherapy: the potential of mRNA vaccines as a promising therapeutic approach","volume":"7","author":"Goyal","year":"2024","journal-title":"Adv. Therap."},{"key":"10.1016\/j.bbcan.2025.189515_bb1190","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1454370","article-title":"The transformative potential of mRNA vaccines for glioblastoma and human cancer: technological advances and translation to clinical trials","volume":"14","author":"Tapescu","year":"2024","journal-title":"Front. Oncol."},{"issue":"11_Supplement","key":"10.1016\/j.bbcan.2025.189515_bb1195","doi-asserted-by":"crossref","DOI":"10.1158\/1538-8514.RNADRIVERS24-PR005","article-title":"Abstract B059: modulating the immunosuppressive pancreas tumor microenvironment through intratumoral delivery of cytokine-encoding mRNAs","volume":"23","author":"Parikh","year":"2024","journal-title":"Mol. Cancer Ther."}],"container-title":["Biochimica et Biophysica Acta (BBA) - Reviews on Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002574?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304419X25002574?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T12:06:33Z","timestamp":1768910793000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304419X25002574"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":238,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S0304419X25002574"],"URL":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189515","relation":{},"ISSN":["0304-419X"],"issn-type":[{"value":"0304-419X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advancements in breast cancer mRNA vaccines: Current development and future prospects","name":"articletitle","label":"Article Title"},{"value":"Biochimica et Biophysica Acta (BBA) - Reviews on Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbcan.2025.189515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"189515"}}